Bedrijfsoverzicht
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the development of human polyclonal immunotherapeutic antibodies designed to treat immune system disorders and infectious diseases within the United States. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, a segment characterized by high research and development intensity and long product development cycles. As of the latest reporting period, the firm holds a market capitalization of $263.53M and employs a workforce of 86 individuals, while its reported annual revenue is not available in the current dataset. The market capitalization of $263.53M indicates that SAB Biotherapeutics holds a mid-cap classification, suggesting it has moved beyond the micro-cap stage but is still in a phase where valuation is heavily influenced by pipeline potential rather than established cash flow generation. The absence of reported revenue figures alongside a significant market cap highlights the early-stage nature of the business, where investor capital is primarily deployed into asset development rather than commercialization, a common structural characteristic for clinical-stage biotechnology entities.
Financiële gezondheid
The company reports a Net Income of $4.26M over the trailing twelve months, yet it simultaneously records an EBITDA of $-45,871,776, revealing a substantial divergence between accounting profit and operational cash earnings driven by significant non-cash charges or asset impairment costs not captured in net income. Free Cash Flow stands at $-21,992,690, indicating that the company is currently burning cash to fund its operations and research programs, which limits immediate financial flexibility but is typical for development-stage firms. All three reported margin metrics—Gross Margin, Operating Margin, and Profit Margin—are listed as 0.0%, which reflects the accounting treatment of the company's clinical-stage assets where traditional margin calculations may be distorted by lack of sales or specific capitalization of R&D expenditures. Despite the negative EBITDA, the balance sheet maintains $96.59M in cash against total debt of $5.95M, creating a net cash position that provides a substantial buffer against operational shortfalls. The Debt to Equity ratio is recorded at 3.93, a figure that appears leveraged on the surface but is mitigated by the strong cash position, suggesting the company relies on equity financing rather than debt obligations to fund its trajectory. Liquidity is exceptionally strong with a Current Ratio of 9.46, indicating that the company possesses nearly ten times the current assets required to cover its short-term liabilities without needing external financing. Return on Equity is 15.0%, while Return on Assets is -28.2%, a combination that suggests management is effectively utilizing shareholder equity, though the negative asset return points to the heavy capitalization of intangible assets or the accounting impact of the company's current lack of commercial revenue streams.
Waarderingsbeoordeling
The Trailing P/E Ratio is N/A due to the specific earnings structure, while the Forward P/E is listed as -11.36, implying that analysts project future earnings that are still negative or that the current earnings base does not align with traditional multiple valuation models for a pre-commercial entity. The Price to Book ratio is 1.18, suggesting that the market values the company's equity at a slight premium to its book value, which is consistent with firms possessing valuable intangible assets like patent-pending drug candidates that are not fully reflected on the balance sheet. The Price to Sales ratio is N/A, and the EV/EBITDA stands at -2.19, indicating that the enterprise value is being assessed based on historical cash burn rather than current profitability, a standard approach for clinical-stage companies lacking a revenue history. The stock has exhibited significant volatility within the past year, trading between a 52-Week High of $6.60 and a 52-Week Low of $1.23. Without the current price explicitly listed in the provided facts to calculate the exact percentage deviation, the range demonstrates a wide trading band of $5.37, reflecting the high-risk, high-reward profile typical of biotechnology investments. The Beta is 0.61, which indicates that the stock price tends to be less volatile than the broader market, moving with roughly 39% less intensity than the market index during periods of fluctuation.
Growth & Income
Revenue Growth Year-over-Year and Earnings Growth Year-over-Year are both listed as N/A, preventing a direct comparison of earnings growth rates versus revenue expansion in the traditional sense for this specific reporting period. Because the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute cash to shareholders, which is a strategic decision typical for biotechnology firms that reinvest all available capital and generated cash into research and development to accelerate clinical trials. This reinvestment strategy prioritizes pipeline advancement and asset expansion over providing current income to investors, effectively deferring dividend payments until a product reaches commercialization and generates sustainable cash flows. Consequently, the overall growth and income profile of SAB Biotherapeutics is characterized by a complete reliance on capital appreciation potential and pipeline milestones rather than dividends or established revenue growth metrics.